Promoting the Use of Generic Drugs and Proactive Initiatives in Home Healthcare
First written in FY2018-Q1. 10 of 14 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「The company implemented initiatives to increase sales per store and focused on expanding community-coordination pharmacies and pharmacies linked to specialized medical institutions, as well as addressing home healthcare needs.」
The Group continues to address home healthcare and expand community-coordinating pharmacies and pharmacies coordinating with specialist medical institutions. - FY2025RestatedAnnual report
「The company implemented initiatives to increase sales per store and focused on expanding community-coordination pharmacies and pharmacies linked to specialized medical institutions, as well as addressing home healthcare needs.」
The Group continues to expand community-coordinating pharmacies and pharmacies coordinating with specialist medical institutions, increase sales per store, and address home healthcare. - FY2024-Q2RestatedAnnual report
「The Group is also expanding initiatives to meet the needs of patients who have difficulty visiting pharmacies, led by its subsidiary 株式会社ヘルシー薬局.」
The Group continues to expand its response to the home healthcare market for patients who have difficulty visiting pharmacies, led by 株式会社ヘルシー薬局. - FY2024-Q1RestatedAnnual report
「To address the needs of patients who have difficulty visiting pharmacies, the Group is responding to expanding demand, led by its subsidiary 株式会社ヘルシー薬局.」
The Group continues to address the home healthcare market, led by 株式会社ヘルシー薬局, in response to growing demand from patients who have difficulty visiting pharmacies. - FY2023RestatedAnnual report
「In response to growing demand, the Group is pursuing home healthcare market initiatives to meet the needs of patients who have difficulty visiting pharmacies, led by its subsidiary 株式会社ヘルシー薬局. These initiatives are also steadily taking hold at existing stores.」
The Group continues to pursue home healthcare market initiatives led by 株式会社ヘルシー薬局 and is also advancing their adoption at existing stores. - FY2023-Q3RestatedAnnual report
「Initiatives in the home healthcare market to meet the needs of patients who have difficulty visiting pharmacies are being led by 株式会社ヘルシー薬局, a subsidiary specializing in home care management guidance, and are gradually taking hold at existing stores as well.」
The Group continues to lead its home healthcare market initiatives through 株式会社ヘルシー薬局, which specializes in home care management guidance, while continuing to embed these initiatives in existing stores. - FY2023-Q2RestatedAnnual report
「We are also steadily advancing initiatives in the home healthcare market to meet the needs of patients who have difficulty visiting pharmacies.」
The Group continues to advance initiatives in the home healthcare market to meet the needs of patients who have difficulty visiting pharmacies. - FY2023-Q1ReframedAnnual report
「We are also focusing on the home healthcare market to meet the needs of patients who have difficulty visiting pharmacies, thereby fulfilling the mission of pharmacists and creating pharmacies chosen by local residents.」
In addition to the previous references to strengthening generic drug sales and in-home services, the filing clearly identifies the home healthcare market serving patients who have difficulty visiting pharmacies as a key focus area. - FY2021-Q2RestatedAnnual report
「The Group prioritizes safety above all else and is working to build pharmacies trusted by local communities, where pharmacists fulfill their expected roles through family pharmacy services, home-care services and other activities.」
The Group continues to promote the role of pharmacists, including in-home services, as an initiative to strengthen pharmacy functions. - FY2020-Q2RestatedAnnual report
「In the pharmaceutical wholesale business, revenue and profit increased through active sales efforts, including developing new customers and focusing on expanding sales of newly listed products.」
The Group continues to develop new customers and focus on expanding sales of newly listed products in connection with strengthening sales of generic drugs and other products. - FY2020-Q1AdvancedAnnual report
「In the pharmaceutical wholesale business, revenue and profit increased through active sales efforts, including developing new customers and focusing on expanding sales of newly listed products.」
As measures to strengthen sales of generic drugs and other products, the filing specifies developing new customers and focusing on expanding sales of newly listed products, contributing to higher revenue and profit in the pharmaceutical wholesale business. - FY2019RestatedAnnual report
「In the pharmaceutical wholesale business, we promoted measures to strengthen generic drug sales.」
The filing continues to describe measures to strengthen generic drug sales in the pharmaceutical wholesale business. - FY2018SoftenedAnnual report
「In the pharmaceutical wholesale business, we promoted measures to strengthen generic drug sales.」
Among the previous initiatives to promote generic drug use and expand home healthcare, this filing explicitly identifies strengthening generic drug sales in the pharmaceutical wholesale business. - FY2018-Q1First statedAnnual report
「Pharmacy dispensing fees recovered and profit increased through measures including promoting the use of generic drugs and proactively expanding home healthcare.」
As specific measures to address the impact of revisions to pharmacy dispensing fees, the filing describes promoting the use of generic drugs and expanding home healthcare.